Clinical Trial Update: Multi-Center, Pediatric, Open-Label, Preference Study of Desloratadine 2.5 mg Reditab (SCH34117) and Zyrtec ® 5.0 mg Chewable Tablet Medications (Study P04573) (Completed) [Phase 4]

View source ↗

Summary

A multi-center pediatric open-label trial comparing desloratadine 2.5 mg Reditab and cetirizine 5 mg chewable in children with allergies completed in Phase 4.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Allergies

Drugs mentioned

• Desloratadine 2.5 mg Reditab (desloratadine)
• Zyrtec 5.0 mg Chewable Tablet (cetirizine)

Snippet

Sponsor: Organon and Co | Conditions: Allergies | Phase 4 | Status: COMPLETED | Results posted: 2010-07-30